Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein.
2013
Nicholas Glanville | Gary R McLean | Bruno Guy | Valerie Lecouturier | Catherine Berry | Yves Girerd | Christophe Gregoire | Ross P Walton | Rebecca M Pearson | Tatiana Kebadze | Nicolas Burdin | Nathan W Bartlett | Jeffrey W Almond | Sebastian L Johnston
Human rhinovirus (RV) infections are the principle cause of common colds and precipitate asthma and COPD exacerbations. There is currently no RV vaccine, largely due to the existence of ∼150 strains. We aimed to define highly conserved areas of the RV proteome and test their usefulness as candidate antigens for a broadly cross-reactive vaccine, using a mouse infection model. Regions of the VP0 (VP4+VP2) capsid protein were identified as having high homology across RVs. Immunization with a recombinant VP0 combined with a Th1 promoting adjuvant induced systemic, antigen specific, cross-serotype, cellular and humoral immune responses. Similar cross-reactive responses were observed in the lungs of immunized mice after infection with heterologous RV strains. Immunization enhanced the generation of heterosubtypic neutralizing antibodies and lung memory T cells, and caused more rapid virus clearance. Conserved domains of the RV capsid therefore induce cross-reactive immune responses and represent candidates for a subunit RV vaccine.
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals